Victoza

(Liraglutide)

Victoza

Drug updated on 11/16/2023

Dosage FormInjection (subcutaneous; 6mg/ml (0.6 mg, 1.2 mg, 1.8 mg)
Drug ClassGlucagon-like peptide-1 (GLP-1) receptor agonist
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
  • Indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.

Product Monograph / Prescribing Information

Document TitleYearSource
Victroza (liraglutide) Prescribing Information.2023Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines